Surgical microwave ablation for multifocal non-resectable liver metastases: a single institution experience treating five or more liver lesions.
暂无分享,去创建一个
E. Jensen | S. Marmor | B. Spilseth | K. McEachron | J. Ankeny | Jillian K. Wothe | R. Schat | C. LaRocca
[1] E. Jensen,et al. Surgical microwave ablation of otherwise non-resectable colorectal cancer liver metastases: Expanding opportunities for long term survival. , 2020, Surgical oncology.
[2] A. Jemal,et al. Colorectal cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[3] E. Jensen,et al. Tumor Lysis Syndrome After Laparoscopic Microwave Ablation of Colorectal Liver Metastases , 2019, Journal of Gastrointestinal Cancer.
[4] J. Engstrand,et al. Colorectal cancer liver metastases – a population-based study on incidence, management and survival , 2018, BMC Cancer.
[5] H. Moon,et al. Advantages of Laparoscopic Radiofrequency Ablation Over Percutaneous Radiofrequency Ablation in Hepatocellular Carcinoma , 2017, Digestive Diseases and Sciences.
[6] J. Ledermann,et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial , 2017, Journal of the National Cancer Institute.
[7] Yahong Sun,et al. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases , 2017, Oncotarget.
[8] William H. Bisson,et al. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions , 2017, Cellular and molecular gastroenterology and hepatology.
[9] Graeme J. Poston,et al. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience , 2015, Surgery Today.
[10] Yuman Fong,et al. A Retrospective Comparison of Microwave Ablation vs. Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases , 2014, Annals of Surgical Oncology.
[11] E. Van Cutsem,et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Fuchs,et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.